Physician

Selena Juarez Stuart, M.D.

According to 2025 Medicare claims, Selena Stuart, M.D. (NPI: 1629236575) practices hematology/oncology in the San Antonio-New Braunfels, TX market, with the plurality of this provider's patient population coming from Comal, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 78130-3162. Stuart is affiliated with the CHSPSC ACO 17, LLC (ACO ID: A3694), CHSPSC ACO 14, LLC (ACO ID: A3724), Alabama Physician Network, LLC (ACO ID: A3738), and Main Street Rural Health Hickory ACO LLC (ACO ID: A5334), participating under the MSSP model.

Stuart's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 781 traditional Medicare patients, billed 216,915 HCPCS/CPT codes, and received $4,181,850 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,209 prescription claims across 359 beneficiaries totaling $5,515,854 in drug costs, led by Revlimid (Lenalidomide). DME data shows 26 claims. Open Payments data shows 26 records totaling $29,399. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $107,393 to $4,181,850. Similarly, Part D prescription costs have moved sharply higher in recent years, from $12,064 to $5,515,854. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	373	1,500	$107,393
2017	354	1,453	$114,076
2018	386	1,511	$119,197
2019	364	1,513	$108,189
2020	354	8,449	$171,819
2021	713	165,973	$2,404,428
2022	818	308,408	$5,369,016
2023	749	241,945	$4,372,973
2024	781	216,915	$4,181,850

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	16	48	$12,064
2016	114	601	$1,043,254
2017	119	661	$1,621,036
2018	146	950	$2,491,885
2019	167	1,204	$4,105,622
2020	159	963	$2,970,143
2021	220	793	$1,255,421
2022	332	1,981	$4,109,328
2023	337	2,043	$4,334,309
2024	359	2,209	$5,515,854

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	11	$277
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	59	$4,699
2022	N/R	12	$255
2023	N/R	45	$8,627
2024	N/R	26	$706

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	239	553	$91
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	372	684	$63
80053	Blood test, comprehensive group of blood chemicals	438	1,408	$10
36415	Insertion of needle into vein for collection of blood sample	429	1,551	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	441	1,560	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	67	1,855	$1,059,503
Pomalyst	Pomalidomide	38	1,064	$904,388
Cabometyx	Cabozantinib S-Malate	20	600	$514,362
Erleada	Apalutamide	27	810	$336,116
Xtandi	Enzalutamide	24	720	$332,071

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	13	$499
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	13	$207

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	11	$626	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	15	$28,773	Janssen Research & Development, LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Selena Juarez Stuart, M.D.?

Tedicare shows public-source Medicare data for Selena Juarez Stuart, M.D. (NPI 1629236575), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Selena Juarez Stuart, M.D. have ACO affiliation data?

Selena Juarez Stuart, M.D. is shown with ACO affiliation data for CHSPSC ACO 17, LLC (MSSP, ACO ID A3694), CHSPSC ACO 14, LLC (MSSP, ACO ID A3724), Alabama Physician Network, LLC (MSSP, ACO ID A3738), and Main Street Rural Health Hickory ACO LLC (MSSP, ACO ID A5334).

What billing organization is linked to Selena Juarez Stuart, M.D.?

Selena Juarez Stuart, M.D. is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Selena Juarez Stuart, M.D. have Open Payments data?

Selena Juarez Stuart, M.D. has 26 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.